Physician profile
Hunter J Hicks
NPI 1043835804
$2,632.19
in general payments reported to CMS, 2019-2025
24 companies · $1,152 in 2025
The $1,152 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $29.50 · 2023: $410 · 2024: $1,041 · 2025: $1,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,602.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $805.86 | 2023-2025 | |
| Novo Nordisk INC | $384.38 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $288.60 | 2023-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $285.68 | 2023-2025 | Caplyta |
| Pfizer INC. | $190.32 | 2024-2025 | |
| Axsome Therapeutics, INC. | $125.52 | 2023-2025 | Auvelity |
| Lilly USA, LLC | $95.97 | 2023-2025 | Zepbound, Mounjaro |
| Horizon Therapeutics Plc | $59.16 | 2023 | Uplizna |
| Lundbeck LLC | $42.84 | 2023-2024 | Vyepti |
| Merck Sharp & Dohme LLC | $41.70 | 2020-2024 | Verquvo, Vaxneuvance, Vaxelis |
| Exact Sciences Corporation | $41.41 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.35 | 2024-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $33.39 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $27.56 | 2024-2025 | Airsupra |
| Inari Medical, INC. | $26.99 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $20.47 | 2025 | Gemtesa |
| Hologic Sales and Service, LLC | $17.98 | 2024 | Aptima |
| Glaxosmithkline, LLC. | $17.36 | 2024 | Arexvy, Shingrix |
| Corium, LLC | $16.48 | 2024 | Azstarys |
| Pulmonx Corporation | $15.84 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Harmony Biosciences LLC | $15.71 | 2023 | Wakix |
| Phathom Pharmaceuticals, INC. | $14.42 | 2024 | Voquezna |
| Dexcom, INC. | $14.12 | 2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $14.08 | 2024 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hunter Hicks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.